ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease
October 30, 2020Kala Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. -
Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial
March 12, 2020Kala Pharmaceuticals said that its dry eye disease candidate KPI-121 0.25% has delivered positive results in a phase 3 trial called STRIDE 3. -
FDA Accepts New Drug Application for KPI-121 0.25%
December 29, 2018Kala Pharmaceuticals announced the New Drug Application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing......
Pharma Sources Insight January 2025
